Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 8/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5181697 | 0.97 | CA1 (0.48) | FKBP1ACA1CA2POLBKMT2A | |
| SCHEMBL12765348 | 0.94 | — | — | |
| SCHEMBL12765346 | 0.88 | — | — | |
| Trifluoroacetic Acid SCHEMBL31726675 | 0.80 | FKBP1A (0.37) | FKBP1ACA1CA2POLBKMT2A | |
| SCHEMBL8212032 | 0.79 | SMN1; SMN2 (0.41) | POLBKMT2ATSHRL3MBTL1HSD17B10 | |
| SCHEMBL1446073 | 0.77 | CA12 (0.54) | POLBTSHRL3MBTL1 | |
| SCHEMBL1378156 | 0.77 | — | — | |
| SCHEMBL1022600 | 0.77 | KDM4E (0.46) | POLBKMT2ATSHRMAPK1KDM4E | |
| SCHEMBL1376664 | 0.77 | FKBP1A (0.32) | FKBP1A | |
| SCHEMBL9988905 | 0.75 | FKBP1A (0.33) | FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114555189-B | Zanthoxylum nitidum base derivatives as inhibitors of topoisomerase IB (TOP 1) and/or tyrosyl-DNA phosphodiesterase 1 (TDP 1) | 美国政府健康及人类服务部 | 2024-08-02 | — | — | CN | disclosed |
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | SHOUTI INC. | 2023-06-01 | — | — | US | disclosed |
| EP-4006028-A1 | IRAK4 KINASE INHIBITOR AND PREPARATION METHOD THEREFOR | Zhuhai Yufan Biotechnologies Co., Ltd (CN) | 2022-06-01 | — | — | EP | disclosed |
| EP-3307738-B1 | ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | UNIV MICHIGAN REGENTS (US) | 2022-04-20 | — | — | EP | disclosed |
| US-10968199-B2 | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200062727-A1 | CYCLOALKYL-CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-10544146-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2020-01-28 | — | — | US | disclosed |
| US-10030019-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2018-07-24 | — | — | US | disclosed |
| EP-3150600-B1 | DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR | QILU PHARMACEUTICAL CO LTD (CN) | 2018-06-27 | — | — | EP | disclosed |
| US-20170197986-A1 | DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2017-07-13 | — | — | US | disclosed |
| US-20080193413-A1 | Anti-Infective Agents | ABBOTT LABORATORIES (US) | 2008-08-14 | — | — | US | disclosed |
| US-7378414-B2 | Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone | ABBOTT LABORATORIES (US) | 2008-05-27 | — | — | US | disclosed |
| WO-2008021733-A2 | TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021871-A2 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007146695-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293497-A1 | 2,3,4,6-Substituted Pyridyl Derivative Compounds Useful As Beta-Secretase Inhibitors For The Treatment Of Alzheimer's Disease | MERCK SHARP & DOHME LLC | 2007-12-20 | — | — | US | disclosed |
| CN-101061113-A | 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK & CO INC (US) | 2007-10-24 | — | — | CN | disclosed |
| EP-1817311-A2 | 2,3,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006057945-A2 | 2,3,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| WO-2005087721-A2 | COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544146-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | NR0B1, NR2E1, NR0B2 | FKBP1A 2803/4885CA1 2376/4885CA2 1571/4885 |
| US-20080193413-A1 | Anti-Infective Agents | POLI, RPL5, POLRMT | FKBP1A 3508/4885CA1 4558/4885CA2 4344/4885 |
| US-20070293497-A1 | 2,3,4,6-Substituted Pyridyl Derivative Compounds Useful As Beta-Secretase Inhibitors For The Treatment Of Alzheimer's Disease | BACE1, BACE2, PSEN2 | FKBP1A 2162/4885CA1 2016/4885CA2 3031/4885 |
| US-20200062727-A1 | CYCLOALKYL-CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, BCL2, AIFM1 | FKBP1A 1310/4885CA1 3839/4885CA2 4202/4885 |
| US-10030019-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | NR0B1, NR2E1, NR0B2 | FKBP1A 2803/4885CA1 2376/4885CA2 1571/4885 |
| US-10968199-B2 | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, BCL2, AIFM1 | FKBP1A 1310/4885CA1 3839/4885CA2 4202/4885 |
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | APLNR, AGTR1, AGTR2 | FKBP1A 3485/4885CA1 3105/4885CA2 952/4885 |
| US-20170197986-A1 | DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR | TMBIM6, HAVCR2, HDGF | FKBP1A 2099/4885CA1 4020/4885CA2 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.